Triptan education and improving knowledge for optimal migraine treatment: an observational study
- PMID: 24520930
- PMCID: PMC4231778
- DOI: 10.1111/head.12286
Triptan education and improving knowledge for optimal migraine treatment: an observational study
Abstract
Background: It is generally felt that patient education and patient knowledge regarding triptan use for acute migraine management are important for successful and safe treatment. It is unclear how knowledgeable triptan users are regarding their triptan, how much education occurs when triptans are prescribed, and the impact patient education has on actual patient knowledge regarding triptan use.
Objective: The primary objective was to compare triptan users' self-perceived knowledge and actual knowledge about triptans in patients who report having received triptan education vs patients who report not having received triptan education.
Methods: This was a multicenter prospective observational study of 207 migraine patients who were using triptans for abortive therapy and who were being evaluated as new patients at academic headache specialty clinics in the United States. Patients completed standardized questionnaires regarding their self-perceived knowledge about triptans, their actual knowledge regarding triptans, and the perceived education about the triptan that they had received at the time of prescription.
Results: Although greater than 80% of the subjects reported receiving education about when to take the triptan and the number of doses they could take for headache, only 71.5% reported receiving education about triptan side effects, 64% for the number of triptan doses they could take each week/month, 64% for taking other medications with the triptan, and 49% for medical contraindications to triptan use. Compared with subjects who did not recall receiving education about when to take their triptan, subjects who recalled such education had a statistically significant greater actual knowledge for taking the triptan immediately after a headache begins (91% vs 77%, P = .049; confidence interval [CI]: 0.00-0.33), treating when pain is mild (75% vs 50%, P = .009; CI: 0.04-0.45), understanding that they do not need to fail treatment with over-the-counter medications before taking a triptan (74% vs 42%, P = .001; CI: 0.11-0.51), and recognizing that coronary artery disease is a contraindication to triptan use (40% vs 19%, P = .001; CI: 0.09-0.34).
Conclusion: This study provides evidence that patients who recall having received education at the time of triptan prescribing have greater knowledge regarding optimal triptan use. Triptan users who recalled having received this education had greater recognition of the importance of taking the triptan immediately at the onset of a headache, treating when pain is mild, not needing to fail treatment with over-the-counter medications before taking a triptan, and understanding that coronary artery disease is a contraindication to triptan use.
Keywords: headache; migraine; migraine treatment; patient education; triptan.
© 2013 American Headache Society.
Figures





Similar articles
-
Education and decision making at the time of triptan prescribing: patient expectations vs actual practice.Headache. 2014 Apr;54(4):698-708. doi: 10.1111/head.12308. Epub 2014 Feb 11. Headache. 2014. PMID: 24512184 Free PMC article.
-
Identifying the factors underlying discontinuation of triptans.Headache. 2014 Feb;54(2):278-89. doi: 10.1111/head.12198. Epub 2013 Sep 3. Headache. 2014. PMID: 24001117 Free PMC article.
-
A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthy.Headache. 2013 Jul-Aug;53(7):1134-46. doi: 10.1111/head.12140. Epub 2013 Jun 14. Headache. 2013. PMID: 23773016
-
The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review.BMC Neurol. 2021 Nov 2;21(1):425. doi: 10.1186/s12883-021-02451-x. BMC Neurol. 2021. PMID: 34727873 Free PMC article.
-
Over-the-counter triptans for migraine : what are the implications?CNS Drugs. 2007;21(11):877-83. doi: 10.2165/00023210-200721110-00001. CNS Drugs. 2007. PMID: 17927293 Review.
Cited by
-
A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States.Adv Ther. 2021 Oct;38(10):5087-5097. doi: 10.1007/s12325-021-01781-z. Epub 2021 May 31. Adv Ther. 2021. PMID: 34057676 Free PMC article. Review.
References
-
- Novack DH. Therapeutic aspects of the clinical encounter. J Gen Intern Med. 1987;2(5):346–355. - PubMed
-
- Balint M. The doctor, his patient, and the illness. Lancet. 1955;268(6866):683–688. - PubMed
-
- Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA. 1994;271(20):1609–1614. - PubMed
-
- Agras WS, Horne M, Taylor CB. Expectation and the blood-pressure-lowering effects of relaxation. Psychosom Med. 1982;44(4):389–395. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical